"Andrew Witty, chief executive officer of GlaxoSmithKline (GSK), announced yesterday that GSK will spend up to $80 million during the next 10 years to prevent mother-to-child HIV transmission and to support AIDS orphans and vulnerable children globally.
"Witty also announced a $17 million fund to develop new HIV drugs for children. In addition, he said that GSK intends to collaborate with other companies on fixed-dose combination pills for HIV and that GSK will voluntarily license its drug abacavir (found in Ziagen, Epzicom and Trizivir) to the generic company Aspen Pharmaceuticals."
Read more in POZ/AIDSmeds, July 15, 2009.
0 comments:
Post a Comment